Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9
Roman O. Kowalchuk(Mayo Clinic in Arizona), Kenneth W. Merrell(Mayo Clinic), Robert R. McWilliams(Mayo Clinic in Arizona), Michelle A. Neben Wittich(Mayo Clinic), Sean P. Cleary(University Health Network), Wen Wee(Roswell Park Comprehensive Cancer Center), Mark J. Truty(Mayo Clinic in Arizona), William S. Harmsen(Mayo Clinic), Rondell P. Graham(Mayo Clinic in Arizona), Hunter C. Gits(Pediatric Oncology Group), Christopher L. Hallemeier(Mayo Clinic in Arizona), Rory L. Smoot(Pancreas Centre (Canada)), Michael G. Haddock(Mayo Clinic in Arizona), Scott C. Lester(Mayo Clinic in Arizona), Þorvarður R. Hálfdánarson(Mayo Clinic), Robert C. Miller(Mayo Clinic), Amit Mahipal(Dana-Farber Cancer Institute), Lizhi Zhang(Dalian Maritime University), Dawn Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 12
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|746